Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory ALK Positive Large B-Cell Lymphoma”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)Looking for participantsNCT06834373
What this trial is testing

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Who this might be right for
Large B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent ALK-Positive Large B-Cell Lymphoma+28 more
Mayo Clinic 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541
What this trial is testing

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more
Mayo Clinic 10
Testing effectiveness (Phase 2)UnknownNCT04796857
What this trial is testing

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Who this might be right for
Non-GCB/ABC Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Early research (Phase 1)Looking for participantsNCT06176690
What this trial is testing

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Who this might be right for
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Baylor College of Medicine 90
Testing effectiveness (Phase 2)UnknownNCT04476459
What this trial is testing

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 33
Testing effectiveness (Phase 2)Ended earlyNCT04676360
What this trial is testing

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Who this might be right for
Relapsed Plasmablastic LymphomaRefractory Plasmablastic LymphomaAnaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Jacob Soumerai, MD 10